Symbiotec Pharmalab Ltd

Earnings Call

Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways

Symbiotec reported Q1 FY27 Revenue of ₹218 Cr, but underlying PAT remains soft due to heavy pre-operative expense drags from unmonetized new business segments.

Call

Guides 20% growth

Results Update

Symbiotec Pharmalab Results Update

Symbiotec Pharmalab released its Q1FY27 investor update. The company reported consolidated revenue of Rs. 218.2 Crore and PAT of Rs. 14.1 Crore for the period.

Earnings Call

Symbiotec Pharmalab Investor Presentation: Key Takeaways

Symbiotec Pharmalab Q1FY27 results show steady 7% revenue growth in core API business, offset by high opex/depreciation from significant new capex in Injectables and CDMO services.

Financial Results

Symbiotec Pharmalab Q1 FY27 Results: Net Profit ₹14.1 Cr, Down 52.8% YoY

Symbiotec Pharmalab Ltd reported revenue from operations of ₹218.2 Cr (+7.4% YoY) and net profit of ₹14.1 Cr (-52.8% YoY) for Q1 FY27.

Key figure

Net profit ₹14.1 Cr · -52.8% YoY